Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP14 | P50281 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294327 | 0.86 | PTGS2 (0.44) | PTGS2POLBMAPTPKMMMP2 | |
| SCHEMBL2294089 | 0.84 | PTGS2 (0.37) | PTGS2POLBMAPTPKMMMP2 | |
| SCHEMBL15967675 | 0.82 | ELANE (0.44) | ELANE | |
| SCHEMBL15984584 | 0.82 | LMNA (0.49) | POLBMAPTELANE | |
| SCHEMBL15984572 | 0.82 | LMNA (0.49) | POLBMAPTELANE | |
| SCHEMBL15967677 | 0.82 | ELANE (0.44) | ELANE | |
| SCHEMBL15987256 | 0.81 | ELANE (0.42) | POLBELANE | |
| SCHEMBL16003524 | 0.81 | ELANE (0.42) | MAPTELANECYP11B1CYP11B2 | |
| SCHEMBL15987201 | 0.81 | ELANE (0.42) | POLBELANE | |
| SCHEMBL16003540 | 0.81 | ELANE (0.42) | MAPTELANECYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516023-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2026-01-06 | — | — | US | disclosed |
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| US-7989641-B2 | Methods of synthesizing N-hydroxysuccinimidyl carbonates | XENOPORT, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989641-B2 | Methods of synthesizing N-hydroxysuccinimidyl carbonates | XENOPORT, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2010017498-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017504-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | PTGS2 1669/4885POLB 2368/4885MAPT 4368/4885 |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | PTGS2 981/4885POLB 2380/4885MAPT 1373/4885 |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | CPS1, SI, ASNS | PTGS2 1409/4885POLB 3181/4885MAPT 4426/4885 |
| US-10815199-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | PTGS2 981/4885POLB 2380/4885MAPT 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.